 |
|
|
| |
Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir
Alafenamide in ART-Naïve Adults
|
| |
| |
17thEuropean AIDS Conference (EACS), 6-9 November 2019, Basel, Switzerland
Reported by Jules Levin
Chloe Orkin,1 Paul E. Sax,2 Jose Arribas,3 Samir Gupta,4 Claudia Martorell,5 Jeffrey L. Stephens,6 Hans-Jürgen Stellbrink,7 Edwin DeJesus,8 Franco Maggiolo,9 Hailin Huang,10 Rima Acosta,10 Diana M. Brainard,10 Sean E. Collins,10 Hal Martin,10 on behalf of the Study 1489 and 1490 Investigators
1Barts Health NHS Trust, London, UK; 2Brigham and Women's Hospital, Boston, Massachusetts, USA; 3Hospital Universitario La Paz, Madrid, Spain; 4Indiana University School of Medicine, Indianapolis, Indiana, USA; 5Infectious Disease and The Research Institute, Springfield, Massachusetts; 6Mercer University School of Medicine, Macon, Georgia, USA; 7ICH Study Center, Hamburg, Germany; 8Orlando Immunology Center, Orlando, Florida, USA; 9ASST Papa Giovanni XXIII, Bergamo, Italy; 10Gilead Sciences, Inc., Foster City, California, USA
References: 1. EACS European AIDS Clinical Society. Guidelines Version 9.1, October 2018. https://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf; 2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Dep of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003510.pdf; 3. Saag MS, et al. JAMA 2018;320:379-96.
|
| |
|
|
|
|
|
